- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01207492
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
January 22, 2024 updated by: Andrew J. Wagner, MD, PhD
A Multi-Center Single Agent Phase II Study of the Efficacy of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Nilotinib is a drug that is used to treat a form of a blood cancer called leukemia.
Nilotinib works by blocking the action of a protein that might be important for the growth of pigmented villonodular synovitis (PVNS).
In this research study the investigators are testing whether nilotinib can stop the growth of PVNS or improve the symptoms experienced from PVNS.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
- In this research study, each cycle of study drug dosing will last 4 weeks (28 days). During each cycle, participants will take nilotinib by mouth twice daily. During the first cycle, participants will come to the clinic on Days 1 and 8. For Cycles 2-4 and every 3 cycles thereafter, they will come to the clinic on Day 1.
- The following tests and procedures will be performed at specific time points during study treatment: MRI or CT scans; physical examinations; vital signs; blood work; questionnaires and EKG.
- Participants may continue in this research study for as long as they do not have serious side effects or their disease does not get worse.
Study Type
Interventional
Enrollment (Actual)
17
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Santa Monica, California, United States, 90403
- Sarcoma Oncology Center
-
Stanford, California, United States, 94305
- Stanford University Medical Center
-
-
Florida
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
-
Texas
-
Houston, Texas, United States, 77030
- UT MD Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histologically confirmed diagnosis of recurrent PVNS ( or diffuse-type giant cell tumor or tenosynovial giant cell tumor) that is unresectable, metastatic, or for which the patient refuses surgical intervention
- Progressive disease in the last 12 months, as demonstrated by imaging or clinical appearance of new tumors, in the opinion of the treating investigator
- At least one site of measurable disease according to RECIST 1.1 on MRI (or CT scan for metastatic disease)
- Any number or type of prior systemic therapies, with the exception of known or suspected CSF1 receptor inhibitors as outlined in exclusion criteria below
- 18 years of age or older
- Life expectancy greater than 6 months
- ECOG Performance Status of 0, 1 or 2
- Normal organ and marrow function as defined in the protocol
- QTc less than or equal to 450 ms on 12-lead ECG
- Negative urine or serum pregnancy test within days of start of study drug administration for women of childbearing potential.
- Women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 3 months following study drug discontinuation
Exclusion Criteria:
- Prior treatment with known or suspected CSF1 receptor inhibitor, including nilotinib, imatinib, sunitinib, or sorafenib, or other approved or investigational tyrosine kinase inhibitors used for treatment of diffuse-type giant cell tumor
- Concurrent treatment with other investigational agents
- Inability to tolerate or contraindication to MRI scanning for participants with localized disease
- Impaired cardiac function
- Current treatment with strong CYP3A4 inhibitors that cannot either be discontinued or switched to a different medication prior to starting study drug
- Current treatment with any medications that have the potential to prolong the QT interval and that cannot either be discontinued or switched to a different medication prior to starting study drug
- Impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug
- Acute or chronic pancreatic disease
- Acute or chronic liver disease
- Another primary malignant disease requiring systemic treatment or radiation
- History of significant congenital or acquired bleeding disorder unrelated to cancer
- Major surgery within 28 days prior to Day 1 of the study
- Treatment with other investigational agents within 28 days of day 1
- History of non-compliance to medical regimens or inability to grant consent
- Women who are pregnant or breastfeeding
- Other comorbidities that would interfere with study participation or safety in the opinion of the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nilotinib
Nilotinib 200 mg taken as 400 mg twice daily, continuously
|
Taken orally twice daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Progression Free Survival
Time Frame: 6 months
|
To estimate progression free survival at 6 months in participants with recurrent PVNS treated with nilotinib.
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Tumor Response Rate (OR)
Time Frame: 2 years
|
To determine overall tumor response rate [% complete response (CR) + % partial response (PR) by RECIST 1.1].
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR) is a disappearance of all target lesions.
Partial Response (PR) is a >=30% decrease in the sum of the longest diameter of target lesions.
Overall Response (OR) = CR + PR.
|
2 years
|
Clinical Benefit Rate
Time Frame: 6 months
|
To determine the clinical benefit rate [% CR + % PR + % stable disease by RECIST 1.1] at 6 months.
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR) is a disappearance of all target lesions.
Partial Response (PR) is a >=30% decrease in the sum of the longest diameter of target lesions.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Andrew J. Wagner, MD, PhD, Dana-Farber Cancer Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2010
Primary Completion (Actual)
April 1, 2014
Study Completion (Estimated)
January 1, 2025
Study Registration Dates
First Submitted
September 21, 2010
First Submitted That Met QC Criteria
September 22, 2010
First Posted (Estimated)
September 23, 2010
Study Record Updates
Last Update Posted (Estimated)
January 24, 2024
Last Update Submitted That Met QC Criteria
January 22, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10-179
- YUS23T (Other Identifier: Novartis)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tenosynovial Giant Cell Tumor
-
Deciphera Pharmaceuticals LLCActive, not recruitingTenosynovial Giant Cell Tumor | Giant Cell Tumor of Tendon Sheath | Pigmented Villonodular Synovitis | Tenosynovial Giant Cell Tumor, Diffuse | Tenosynovial Giant Cell Tumor, LocalizedNorway, United States, France, Spain, Hong Kong, Netherlands, Italy, Germany, Australia, United Kingdom, Canada, Poland, Switzerland
-
Deciphera Pharmaceuticals LLCActive, not recruitingAdvanced Malignant Neoplasm | Tenosynovial Giant Cell Tumor | Giant Cell Tumor of Tendon Sheath | Pigmented Villonodular Synovitis | Tenosynovial Giant Cell Tumor, DiffuseUnited States, France, Spain, United Kingdom, Netherlands, Canada, Italy, Australia, Poland
-
Novartis PharmaceuticalsCompletedPigmented Villonodular Synovitis | PVNS | Giant Cell Tumor of the Tendon Sheath | GCCTS | Tenosynovial Giant Cell Tumor Localized or Diffused Type | GCTSUnited States, Switzerland
-
Daiichi Sankyo Co., Ltd.Active, not recruitingTenosynovial Giant Cell TumorTaiwan, China
-
Daiichi Sankyo, Inc.CompletedTenosynovial Giant Cell TumorUnited States, Spain, Taiwan, Australia, Hungary, Italy, Netherlands
-
SynOx Therapeutics LimitedNot yet recruiting
-
Daiichi Sankyo Co., Ltd.RecruitingTenosynovial Giant Cell TumorJapan
-
Daiichi Sankyo, Inc.RecruitingTenosynovial Giant Cell Tumor | HepatotoxicityUnited States
-
Abbisko Therapeutics Co, LtdRecruitingNeoplasms | Tenosynovial Giant Cell TumorUnited States
-
Daiichi Sankyo, Inc.OptimapharmCompletedGiant Cell TumorsUnited States, France, Spain, Netherlands, Italy, Austria, United Kingdom, Germany
Clinical Trials on nilotinib
-
Niguarda HospitalCompletedLeukemia, Myeloid, Chronic-PhaseItaly
-
Novartis PharmaceuticalsTerminatedPulmonary Arterial HypertensionSwitzerland, United States, Germany, Singapore, Korea, Republic of, Canada
-
Georgetown UniversityUnknownParkinson Disease | Parkinsons Disease With DementiaUnited States
-
XSpray MicroparticlesCompleted
-
Shenzhen Second People's HospitalDongguan People's Hospital; Zhongshan People's Hospital, Guangdong, China; The... and other collaboratorsRecruitingChronic Myeloid Leukemia, Chronic Phase | NilotinibChina
-
Novartis PharmaceuticalsNo longer availableHypereosinophilic Syndrome (HES)
-
KeifeRx, LLCWorldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceuticals Industries...Not yet recruiting
-
Novartis PharmaceuticalsNo longer availableAcute Lymphoblastic Leukemia (ALL)
-
Novartis PharmaceuticalsCompleted
-
Sheba Medical CenterCompletedStem Cell Transplantation | Acute Lymphoblastic Leukemia | Chronic Myeloid LeukemiaIsrael